摘要
目的探讨使用依巴斯汀与其联合氯雷他定治疗慢性难治性荨麻疹的临床疗效,及对外周血白细胞介素-4(IL-4)、干扰素-γ(IFN-γ)和免疫球蛋白E(IgE)水平的影响。方法选择2021年10月—2023年10月本院收治的慢性难治性荨麻疹患者195例作为研究对象,使用随机数表法分为对照组98例和研究组97例。对照组予以依巴斯汀治疗,研究组使用依巴斯汀与氯雷他定联合治疗。记录两组患者治疗前、治疗4周后症状体征[瘙痒评分(FIIQ)、风团评分(LFS)、最大风团大小]、免疫指标(IL-4、IFN-γ、IgE)水平,比较治疗前、治疗后6个月两组患者生活质量[荨麻疹活动度(UAS)、慢性荨麻疹生活质量评分(CU-Q2oL)],并统计药物不良反应与治疗后6个月内复发情况。结果治疗4周后,两组患者症状体征(FIIQ、LFS、最大风团大小)、部分免疫指标(IL-4、IgE)均显著低于治疗前,且研究组低于对照组(均P<0.05);IFN-γ显著高于治疗前,且研究组高于对照组(均P<0.05)。治疗6个月后,两组患者生活质量(UAS、CU-Q2oL)显著低于治疗前,且研究组低于对照组(均P<0.05)。研究组不良反应显著高于对照组(P<0.05),治疗后6个月内两组患者复发率差异无统计学意义(P>0.05)。结论使用依巴斯汀联合氯雷他定治疗可以有效改善慢性难治性荨麻疹患者症状体征与复发情况,提高对患者免疫水平状态与预后生活质量,值得临床使用。
Objective To explore the clinical efficacy of Ebastine or Ebastine combined with Loratadine in the treatment of chronic refractory urticaria and influence on levels of peripheral blood interleukin-4(IL-4),interferon-γ(IFN-γ)and immunoglobulin E(IgE).Methods 195 patients with chronic refractory urticaria treated in the hospital from October 2021 to October 2023 were selected as the research subjects,and were divided into 98 cases in control group and 97 cases in study group according to the random number table method.The control group was treated with Ebastine and the study group was given Ebastine combined with Loratadine.The symptoms and signs[Four-Item Itch Questionnaire(FIIQ),Level Four Score(LFS)of wheal,maximum wheal size]and levels of immune indicators(IL-4,IFN-γ,IgE)were recorded in the two groups before treatment and after 4 weeks of treatment.The quality of life scores[Urticaria Activity Score(UAS),Chronic Urticaria Quality Of Life Score(CU-Q2oL)]of the two groups of patients were compared before treatment and at 6 months after treatment,and the adverse drug reactions and recurrence within 6 months after treatment were statistically analyzed.Results After 4 weeks of treatment,the symptoms and signs(FIIQ,LFS,maximum wheal size)and partial immune indicators(IL-4,IgE)of the two groups were significantly lower than those before treatment,and the above indicators of study group were lower than those of control group(all P<0.05).The IFN-γ level was significantly higher than that before treatment,and the level was higher in study group than that in control group(all P<0.05).After 6 months of treatment,the quality of life scores(UAS,CU-Q2oL)were significantly lower in the two groups than those before treatment,and the scores of study group were lower compared with those of control group(all P<0.05).Adverse reactions in study group were significantly more than those in control group(P<0.05),and there was no statistical significance in the recurrence rate between the two groups within 6 months after treatment(P>0.05).Conclusion The application of Ebastine combined with Loratadine can effectively improve the symptoms and signs and recurrence and enhance the immune status and prognosis quality of life of patients with chronic refractory urticaria,therefore it is worthy of clinical application.
作者
季慧琳
薛怀煜
刘庆娜
朱怡迪
魏志平
JI Huilin;XUE Huaiyu;LIU Qingna;ZHU Yidi;WEI Zhiping(Department of Dermatology,The Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu,China)
出处
《西部医学》
2025年第9期1354-1358,共5页
Medical Journal of West China
基金
国家自然科学基金项目(81872493)。
